Retinitis
6
0
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
1 terminated out of 6 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
Ocular Manifestations in Rheumatic Diseases
Screening for NEI Clinical Studies
Stem Cell Transplantation in Ocular Lesions of Behcet's Disease